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Catheter-related infections constitute 10–15% of all nosocomial infections, and constitute
a relevant and growing problem, with an impact that is far from irrelevant, especially in
the intensive care unit. The most frequent pathogens implicated come from the skin flora;
Gram-positive cocci are responsible for about two-thirds of the infections, and Candida
has emerged as another important cause. Questions about drug, route of administration,
dosage and duration of antibiotherapy for patients who have become apyretic and with
no signs of sepsis after catheter removal are still under debate, and far from being
definitively answered. Decisions regarding these questions are based on three main
factors: namely, which is the microoorganism responsible for the infection, what was the
time to response, and what kind of patient are we dealing with? However, the micro-
organism is clearly the main factor in making a decision. In summary, all catheter-related
infections should be treated with appropriate antibiotics, regardless of the removal of the
catheter, with parenteral drugs, using high doses and short courses, namely 1 week, and
de-escalating to narrow-spectrum drugs on the basis of susceptibility tests as soon as
possible. Staphylococcus aureus catheter-related infections constitute an exception, need-
ing longer courses, as it is difficult to predict who will be high-risk patients.
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The epidemiology of catheter-related infection
varies widely according to the population and
type of unit, type of device and its site, and the
therapy for which it is used. Catheter-related infec-
tions constitute 10–15% of all nosocomial infec-
tions. For example, they are responsible for 12% of
the nosocomial infections in the EPIC study [1], as
well as in our intensive care unit (ICU) during the
year 1999 (Figure 1). The incidence of central
venous catheter-associated infections also varies
between 2.1 episodes per 1000 catheter days in
respiratory ICUs and 30.2 episodes per 1000 cathe-
ter days in burn ICUs in the USA, and in the latest
report it was 5.3 episodes per 1000 catheter days
[2]. The ENVIN Study in Spain shows that this is
not only a relevant problem, but also a growing
one.
The impact of these infections is not as irrelevant
as is sometimes thought. Crude mortality varied
between 31.5% and 82.4%, and attributable mor-
tality ranged from 4% to 47% [3–8]. Increases in
both length of stay in hospital and costs are sig-
nificant and undisputable [3,6,8].
The most frequent microorganisms implicated
in catheter-related infections come from the skin
flora, Gram-positive cocci being responsible for
about two-thirds of the infections, and coagu-
lase-negative Staphylococcus being the leading
pathogen. Staphylococcus aureus and Enterococcus
are also common pathogens; Candida spp. have
emerged as an important cause, and Gram-nega-
tive bacilli, namely Pseudomonas aeruginosa and,
less often, Stenotrophomonas maltophila and Acine-
tobacter spp.; other Gram-positive bacteria, such as
Bacillus and Corynebacterium, cannot be neglected
as causative organisms [9].
Infection is usually a late event: more than 50%
of the infections occur after the 14th day following
admission, and, in our unit, Staphylococcus spp.
comprised the cause of all catheter-related infec-
tions occurring in the first week after admission
(Table 1).
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There are three main reasons for removing cen-
tral venous lines in our daily ICU work (1): the
central line becomes unnecessary (2); there is
puncture site suppuration; or (3) there is suspicion
of infection/sepsis without other detectable focus.
For the first two scenarios, systemic antibiotherapy
is not necessary, but for the third one, antibiotics
are usually prescribed empirically. This review
relates to the last situation: what to do with the
patient who becomes apyretic without signs of
sepsis after catheter removal?
There are, currently, two different scenarios,
depending on the results of blood cultures. If
the patient becomes apyretic without signs of
sepsis, central line culture is positive, and blood
cultures are negative, antibiotics should not be
started or, if started, should be stopped. If, on
the other hand, the patient becomes apyretic with-
out signs of sepsis, central line culture is positive,
and blood cultures are also positive with the same
agent, antibiotherapy is usually started or contin-
ued. Is this really the right thing to do?
Despite the large number of cases of central
venous catheter-associated infections occurring
throughout the world, the questions of drug, route
of administration, dosage and duration of therapy
do not appear to have been adequately addressed,
either by randomized controlled trials or by any
other appropriate methods. Consideration does
not even appear to have been given to the possi-
bility that antimicrobial therapy may not be
required at all in some cases.
Decisions regarding these questions are based
on the following factors: which is the microorgan-
ism responsible for the infection, what was the time
to response, and what kind of patient are we deal-
ing with (underlying diseases and complications)
(Figure 2)? As the microorganism is clearly the
main factor in making a therapeutic decision, we
will now discuss the most frequent pathogens [10].
Figure 1 ICU-acquired infections in Unidade de Cuidados
Intensivos Polivalente da Urgeˆncia-Hospital S. Joa˜o-Porto,
during 1999.
Figure 2 Decisions about antibiotherapy.
Table 1 Catheter-related infections: chronological pathogen distribution
3 4 5 6 8 9 11 12 14 15 >20
MRSA X XX X X X XXX
Acinetobacter spp. XX
Coagulase-negative Staph X X
Enterococci X X XX XX
Enterobacteriaceae X X
Pseudomonasþ Stenotrophomonas X X XX
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C O A G U L A S E - N E G A T I V E
S T A P H Y L O C O C C U S
Most of the coagulase-negative Staphylococcus
strains causing catheter-associated infections are
methicillin resistant. Cure rates are not affected by
catheter removal [11,12], but if the central venous
catheter is not removed, there is a 20% chance that
the bacteremia will recur, compared with only a
3% risk of recurrence if the catheter is removed
[11], the risk being especially high if the catheter
stays in place for more than 3 weeks after the
bacteremic episode. Vancomycin and teicoplanin
have been widely used, and the overall efficacies of
both drugs are comparable, with high response
rates [13–15]. Bolus doses of teicoplanin may be
less effective because of limited exposure of the
coagulase-negative staphylococci to the antibiotic
[16]. If time to response is more than 72 h, a 14-day
course of antibiotics should be used, but if time to
response is less than 72 h, a 7-day course is quite
enough [11].
S T A P H Y L O C O C C U S A U R E U S
The catheter must definitely be removed; other-
wise serious infectious complications may arise:
septic thrombosis, severe sepsis and/or deep-
seated infections [17]. Also, retention of the cathe-
ter can lead to persistence of Staphylococcus aureus
bacteremia, to relapse, and to increased mortality;
only 18% of all infected patients and only 10% of
those with exit-site infection were cured without
catheter removal [18].
Conventional treatment for any Staphylococcus
aureus bacteremia has been a 4–6-week course of
antibiotics, on the basis that: (1) classical physical
findings of endocarditis are not usually present,
making it difficult to exclude this diagnosis; (2)
the sensitivity of two-dimensional echocardiogra-
phy for detecting vegetation in S. aureus endocar-
ditis seems to be as low as 59%; and (3) there is
a high prevalence of endocarditis among cases of
S. aureus bacteremia [19]. There is a tendency,
however, to reduce the duration of antibiotherapy
to a 2- or 4-week course. Two large retrospective
trials showed that there was no recurrence after
catheter removal followed by at least 10 days of
antibiotics [17,20], and that treatment of uncom-
plicated S. aureus bacteremia for less than 10 days
was associated with a significantly higher rate of
relapse. Rahal et al. [21] performed the only
randomized trial that addressed the question of
late complication rate, but it was small, and the
results showed no significant difference between
those given short-course therapy and those treated
for 4 weeks. A meta-analysis [22] including 11
studies and 132 patients, from 1976 to 1992, using
antibiotherapy for not more than 2 weeks, showed
a percentage of late complications varying
between 0% and 29%, with a pooled estimate of
6.1% (2.0–10.2%). From this meta-analysis, we
may conclude that certain late complications
occur following the short-course regimen, but
the large majority of patients on the short-course
regimen did respond and did not develop
complications.
Therefore, our clinical practice consists of using
a 2-week course of antibiotics for uncomplicated
S. aureus infection, occurring in patients with
no underlying valvular disease who respond
within 3 days, and a 4-week course for patients
with complications such as endocarditis or septic
thrombosis.
C A N D I D A S P P .
Removal of the central venous catheter is clearly
necessary in certain cases [23–26]. In a group of
patients judged suitable for management by cathe-
ter removal alone, disseminated fungal infections
were found in 35% of those who eventually came
to autopsy [27]. In another study [28] with 26
patients treated by central venous catheter
removal alone, four developed endophtalmitis
and three lost their vision. In the case of candida
infection, usually by the time culture results are
available all signs of infection have disappeared;
however our policy consists of treatment for
14 days after the last positive blood culture.
Amphotericin B is used for Candida krusei and
Torulopsis glabrata infections, and fluconazole is
used for all other candida infections [23,24,29].
G R A M - N E G A T I V E B A C I L L I
Pseudomonas aeruginosa, Stenotrophomonas malto-
phila and Acinetobacter spp. are also relatively
common causes of catheter-associated infections.
Removal of the catheter is important, as failure to
remove it results in significantly higher rates of
treatment failure and recurrence of bacteremia,
while the rate of cure is 100%, irrespective of
the appropriateness of antibiotic therapy, if the
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catheter is removed [30]. Some authors accept
that infections caused by Enterobacteriaceae may
be managed by central venous catheter removal
alone (without antibiotics). Nevertheless, a 1-week
course of antibacterial antibiotics is usually given
[31].
G R A M - P O S I T I V E B A C I L L I
To treat infection caused by Corynebacterium
or Bacillus, vancomycin is usually prescribed,
although treatment should be de-escalated on
the basis of susceptibility tests.
C O N C L U S I O N S
In conclusion, all catheter-related infections
should be treated with appropriate antibiotics,
regardless of the removal of the catheter, with
parenteral drugs, using high doses and short
courses, namely 1 week, followed by de-escalation
to narrow-spectrum drugs on the basis of suscept-
ibility tests as soon as possible. Catheter-related
infections caused by S. aureus are an exception, and
require longer courses, as it is difficult to predict
which patients are at high risk.
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